Publications by authors named "J E Layton"

Claim this Profile
P
Protocol for a randomized clinical trial to evaluate the effectiveness of a technology-assisted motivational interviewing (TAMI) chatbot on smoking cessation.
Brian Borsari, Meredith C Meacham, Ahson Saiyed, Tatyana Kanzaveli, Maksim Tsvetovat, John Layton

Contemp Clin Trials· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study.
Catherine B Johannes, Craig I Coleman, Csaba P Kovesdy, Anam M Khan, Ryan Ziemiecki, J Bradley Layton

Diabetes Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.
Shelby S Fisher, Arnstein Lindaas, Stella G Muthuri, Patricia C Lloyd, Joann F Gruber, J Bradley Layton

PLoS One· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumococcal Vaccine Use and Immunogenicity in Patients with Glomerular Disease: A Scoping Review and Analysis of Healthcare Claims Data.
Katherine E Guittari, Young-Hyun Moon, Virginia Pate, Elizabeth O Moreton, Amy Mottl, J Bradley Layton

Glomerular Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.
J Bradley Layton, Ryan Ziemiecki, Catherine B Johannes, Manel Pladevall-Vila, Anam M Khan

Diabetes Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis